RecruitingNCT07351422
Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis
Studying Takayasu arteritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Edinburgh
- Intervention
- Questionnaire(other)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- University of Edinburgh, Edinburgh, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07351422 on ClinicalTrials.govOther trials for Takayasu arteritis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07276087Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy ControlsÖZLEM NUR TOK YAMAN
- RECRUITINGNANCT07491913Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained RemissionMarmara University
- ACTIVE NOT RECRUITINGNCT06807788Evaluation of Platelet Aggregability in Patients with Takayasu's ArteritisJose Carlos Nicolau
- RECRUITINGPHASE4NCT06498089A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's ArteritisShanghai Zhongshan Hospital
- RECRUITINGNANCT06178419Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)Xuanwu Hospital, Beijing
- RECRUITINGPHASE4NCT05102448Comparison of Tofacitinib and Methotrexate in Takayasu's ArteritisShanghai Zhongshan Hospital
- RECRUITINGPHASE4NCT04300686A Pilot Study in Severe Patients With Takayasu Arteritis.Shanghai Zhongshan Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT04161898A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)AbbVie